As Biotechnology companies, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Titan Pharmaceuticals Inc.||6.62M||2.98||9.31M||-2.66||0.00|
|BioDelivery Sciences International Inc.||55.64M||6.35||46.37M||-0.93||0.00|
In table 1 we can see Titan Pharmaceuticals Inc. and BioDelivery Sciences International Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 provides us the net margins, return on equity and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Titan Pharmaceuticals Inc.||-140.63%||-904.1%||-123.4%|
|BioDelivery Sciences International Inc.||-83.34%||-256.9%||-55.9%|
Risk and Volatility
Titan Pharmaceuticals Inc.’s volatility measures that it’s 25.00% less volatile than Standard and Poor’s 500 due to its 0.75 beta. BioDelivery Sciences International Inc.’s 55.00% less volatile than Standard and Poor’s 500 which is a result of the 0.45 beta.
The current Quick Ratio of Titan Pharmaceuticals Inc. is 4.6 while its Current Ratio is 5.2. Meanwhile, BioDelivery Sciences International Inc. has a Current Ratio of 3 while its Quick Ratio is 2.8. Titan Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than BioDelivery Sciences International Inc.
The next table highlights the delivered recommendations and ratings for Titan Pharmaceuticals Inc. and BioDelivery Sciences International Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Titan Pharmaceuticals Inc.||0||0||0||0.00|
|BioDelivery Sciences International Inc.||0||0||5||3.00|
On the other hand, BioDelivery Sciences International Inc.’s potential upside is 48.59% and its average price target is $7.4.
Insider and Institutional Ownership
The shares of both Titan Pharmaceuticals Inc. and BioDelivery Sciences International Inc. are owned by institutional investors at 5.2% and 58.1% respectively. Insiders owned roughly 3.1% of Titan Pharmaceuticals Inc.’s shares. Insiders Comparatively, owned 4.7% of BioDelivery Sciences International Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Titan Pharmaceuticals Inc.||-5.98%||40.65%||-15.94%||-62.11%||-70.03%||29.3%|
|BioDelivery Sciences International Inc.||-3.96%||4.98%||38.57%||65.81%||115.56%||31.08%|
For the past year Titan Pharmaceuticals Inc. was less bullish than BioDelivery Sciences International Inc.
BioDelivery Sciences International Inc. beats on 9 of the 11 factors Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.